PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON

• L. Rosinol,
• S. Z. Usmani,
• N. Bahlis,
• A. Y. Krishnan,
• A. K. Nooka,
• A. Oriol,
• M. Delforge,
• A. L. Garfall,
• N. W. van de Donk,
• P. Rodríguez Otero,
• T. G. Martin,
• J. Diels,
• S. Van Sanden,
• L. Pei,
• E. Ammann,
• R. Kobos,
• M. Slavcev,
• J. Smit,
• A. Londhe,
• P. Moreau

Affiliations

L. Rosinol

1 Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

S. Z. Usmani

2 Memorial Sloan Kettering Cancer Center, New York, NY, United States of America

N. Bahlis

3 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada

A. Y. Krishnan

4 City of Hope Comprehensive Cancer Center, Duarte, CA

A. K. Nooka

5 Winship Cancer Institute, Emory University, Atlanta, GA, United States of America

A. Oriol

6 Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

M. Delforge

7 University of Leuven, Leuven, Belgium

A. L. Garfall

8 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America

N. W. van de Donk

9 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

P. Rodríguez Otero

10 University of Navarra, Pamplona, Spain

T. G. Martin

11 University of California, San Francisco, CA, United States of America

J. Diels

12 Janssen Pharmaceutica NV, Beerse, Belgium

S. Van Sanden

12 Janssen Pharmaceutica NV, Beerse, Belgium

L. Pei

13 Janssen Research & Development

E. Ammann

14 Janssen Global Services, Raritan, NJ

R. Kobos

13 Janssen Research & Development

M. Slavcev

14 Janssen Global Services, Raritan, NJ

J. Smit

15 Janssen Research & Development, Spring House, PA

A. Londhe

16 Janssen Research & Development, Titusville, NJ, United States of America

P. Moreau

17 Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France